• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Propeller Health, Novartis Co-Package Asthma Medication in Europe for Prescription

by Jasmine Pennic 07/08/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Propeller Health, Novartis Co-Package Asthma Medication in Europe for Prescription

What You Should Know:

– Propeller Health announced it will co-package a new asthma medication from Novartis, which was approved by the European Commission this week for use in the EU.

– Enerzair® Breezhaler® plus Propeller Health sensor is the first asthma medication to be co-packaged and co-prescribed with a digital health platform.

– Propeller’s solution works by attaching a sensor to the Enerzair® Breezhaler® inhaler, which then delivers objective data on medication use to the Propeller app on the patient’s smartphone


Propeller Health today announced a collaboration with Novartis to co-packaged the Propeller digital health platform with Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma. Propeller previously announced a collaboration with Novartis to develop a custom add-on sensor for the Breezhaler® inhaler, a device used for the company’s portfolio of COPD treatments (Ultibro® Breezhaler®, Onbrez® Breezhaler®, and Seebri® Breezhaler®), connecting these medications to Propeller’s digital health platform. The same sensor will be co-packaged with Enerzair® Breezhaler®.

Why It Matters

This collaboration marks the first time a digital health tool will be packaged and prescribed alongside an inhaled asthma medication. Enerzair® Breezhaler® and Propeller sensor and app received approval from the European Commission in July and will launch across Europe starting in 2020. Healthcare professionals in Europe will have the option to prescribe Enerzair® Breezhaler® with or without the companion digital health platform. The medication is not available in the U.S.

Enerzair® Breezhaler® was approved as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.

Impact of Uncontrolled Asthma

Asthma affects an estimated 358 million people worldwide and can cause a significant personal, health, and financial burden when not adequately controlled. Despite current therapy, over 40% of patients with asthma at Global Initiative for Asthma (GINA) Step 3, and over 45% at GINA Steps 4 and 5 remain uncontrolled. Patients with uncontrolled asthma may downplay or underestimate the severity of their disease and are at a higher risk of exacerbation, hospitalization, or death. Barriers, such as less than optimal adherence, incorrect inhaler technique, treatment mismatch, safety issues with oral corticosteroids, and ineligibility for biologics, have created an unmet medical need in asthma.

Enerzair Breezhaler 

Enerzair Breezhaler is provided in a transparent capsule that allows patients to see that they have taken their medication and will be administered via the dose-confirming Breezhaler® device, which enables once-daily inhalation using a single inhaler. The digital companion includes a sensor that attaches to the Breezhaler device and can be linked to the Propeller Health smartphone app, providing patients with inhalation confirmation, medication reminders, and access to objective data that can be shared with their physician in order to help them make better therapeutic decisions.

Propeller’s solution works by attaching a sensor to the Enerzair® Breezhaler® inhaler, which then delivers objective data on medication use to the Propeller app on the patient’s smartphone. The app also sends the patient reminders to take their prescribed dose and keeps a record of adherence data over time. The patient can share that data with their clinician to help inform the patient’s treatment plan.

In previous clinical studies unrelated to this collaboration, the Propeller platform has been shown to increase asthma control by up to 63 percent, increase medication adherence by up to 58 percent, and reduce asthma-related emergency department visits and hospitalizations by as much as 57 percent.

“Our collaboration with Novartis to co-package Propeller with Enerzair® Breezhaler® is the first time a pharmaceutical company and digital health company have worked together to package a digital health platform with an asthma medication,” said David Van Sickle, co-founder and CEO of Propeller Health. “The ability to prescribe a maintenance medication with Propeller will make it easier for healthcare professionals to engage their patients in self-management.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Asthma, COPD, digital health, medication, Medication Adherence, Novartis, Propeller Health, risk

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Cigna to Acquire Express Scripts for $67B: 5 Things to Know

Cigna and Humana Merger Talks Could Face Antitrust Scrutiny

RNSA23: Cleveland Clinic and Canon Partner to Pioneer Next-Gen Imaging Technologies

RSNA23: Cleveland Clinic and Canon to Establish Comprehensive Imaging Research Center

Automating Implant Orders: A Turning Point in Healthcare’s Digital Transformation

Automating Implant Orders: A Turning Point in Healthcare’s Digital Transformation

Consumers Believe Generative AI Can Revolutionize Healthcare

71% of Consumers Believe Generative AI Can Revolutionize Healthcare

NCQA Launches Virtual Care Accreditation Pilot

NCQA Launches Virtual Care Accreditation Pilot

Novant Health Acquires Three Tenet Hospitals in South Carolina for $2.4 Billion

M&A: Novant Health Acquires 3 Tenet Hospitals in South Carolina for $2.4B

UnitedHealthcare Launches Virtual Prescription Renewal Option

UnitedHealthcare Accused of Using Faulty AI Model to Deny Healthcare Claims to Elderly Patients

Meet The Circular Smart Ring Slim, The Slimmest and Lightest Smart Ring in the World

Meet The Circular Smart Ring Slim, The Slimmest and Lightest Smart Ring in the World

MIT Spun Out Layer Health Launches with $4M to Build the AI Layer for Healthcare

MIT Spun Out Layer Health Launches with $4M to Build the AI Layer for Healthcare

Edge Computing's Role in Shaping the Future of Wearable Healthcare

Edge Computing’s Role in Shaping the Future of Wearable Healthcare

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |